Evidence map›Paper›PMID 42024234›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

Investigating the therapeutic effects of caffeine-naringenin combination on the repair of intestinal permeability and composition of gut microbiota in obese rats under long-term high-fat diet.

Ahmadreza Dehghani, Arezoo Mirzaei, Marzieh Malakoutikhah, Pouria Karimi, Fouzieh Zadhoush, Maedeh Ghasemi

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Ahmadreza DehghaniStudent Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.ORCID http://orcid.org/0009-0007-0225-5209
Arezoo MirzaeiDepartment of Bacteriology and Virology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Marzieh MalakoutikhahStudent Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Pouria KarimiSchool of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
Fouzieh ZadhoushDepartment of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.ORCID http://orcid.org/0000-0002-2093-6610
Maedeh GhasemiDepartment of Physiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. ghasemi.m.ph@gmail.com.ORCID http://orcid.org/0000-0002-5414-9594

Funding

Isfahan University of Medical Sciences 1402342
6 · The paper itself

Abstract

Obesity-related metabolic dysfunction is closely associated with gut dysbiosis, impaired intestinal barrier function, and endotoxemia, which can induce oxidative stress and liver injury along the gut-liver axis. In this context, caffeine and naringenin were chosen for their potential to address liver injury. Caffeine, a natural methylxanthine, has shown liver-protective properties by modulating lipid metabolism and enhancing antioxidant capacity. Naringenin, a citrus flavonoid, is known for its anti-inflammatory and antioxidant effects and its ability to improve liver function by reducing oxidative stress. This study investigates whether their combination can provide additive or synergistic protection in obese rats sustained on a long-term high-fat diet (HFD). Thirty-five adult male Wistar rats were randomized (n = 7/group) to: control (standard diet), HFD, HFD + caffeine, HFD + naringenin, or HFD + caffeine + naringenin. Obesity was induced by 10 weeks of HFD (≈60% kcal from fat). Treatments were then administered by oral gavage for 6 weeks (caffeine 50 mg/kg/day; naringenin 12.5 mg/kg/day; combination at the same doses). Body weight, BMI/Lee index, lipid profile (TC, TG, LDL, HDL), liver enzymes (AST, ALT, ALP, GGT), systemic oxidative stress markers (MDA, SOD, TAC), and serum LPS (a surrogate of intestinal permeability) were measured. Gut microbiota profiling was done using 16S rRNA V3-V4 Illumina sequencing with standard bioinformatics (e.g., QIIME2). Colon histopathology was evaluated using H&E-stained sections. HFD increased body weight and the Lee index vs. controls, while the combination group showed the largest reductions in both indices. HFD induced dyslipidemia (elevated TC, TG, LDL, and decreased HDL). Caffeine or naringenin alone partially improved lipids, while the combination most effectively normalized them. Microbiota analysis revealed HFD-associated dysbiosis. Monotherapies improved it, and the combination produced the most pronounced eubiotic profile. Intestinal permeability was improved. Serum LPS was significantly elevated in HFD and was reduced by caffeine and, most robustly, by the combination. Systemic redox status improved. HFD altered antioxidant defenses, and treatments increased TAC/SOD, with the combination yielding the most consistent restoration of antioxidant capacity. MDA changes were consistent with attenuated lipid peroxidation under combination therapy. Liver injury markers (AST, ALT, ALP, and GGT) were also ameliorated by the combination. Histopathology of ileum/colon showed HFD-induced inflammatory/architectural damage and a treatment-associated restoration of mucosal structure by the combination. This study demonstrates that the combination of caffeine and naringenin offers a multi-targeted approach to mitigate obesity-related intestinal permeability, microbiota dysbiosis, and liver injury under long-term high-fat diet conditions. The synergistic effects of these compounds not only provide a promising therapeutic strategy for improving metabolic health and liver function but also offer the advantage of minimal side effects, making them a safe and effective option for managing obesity-related complications.

Indexed as

CaffeineFlavanonesGastrointestinal MicrobiomeObesityAnimalsDiet, High-FatIntestinal Barrier FunctionIntestinal MucosaMalePermeabilityRatsRats, WistarCaffeineFlavanonesnaringeninCaffeineEndotoxemiaGut microbiotaHigh-fat dietIntestinal permeabilityNaringenin

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.